Takeda Commits US$100 Million To Regenerative Medicine Startup Ambys

Takeda has committed US$100 million to support the development of therapies for chronic liver diseases at Ambys.

WuXi STA’s Facility Passes Fourth US FDA Inspection

The Jinshan facility is equipped with more than 100 modern reactors for drug manufacturing and houses industry-leading technology platforms for flow chemistry and biocatalysis.

Ascentage Pharma Secures US$150 Million In Series C Funding

Ascentage Pharma will use the funds to further their pipeline of drugs targeting apoptotic pathways for the treatment of cancer and other diseases.

WuXi STA And Antengene To Collaborate On Cancer Drug Development

Antengene is tapping on WuXi STA’s end-to-end drug development platform to accelerate the clinical testing and commercialization of cancer drugs.

US$3.8 Million Awarded To Tackle Antibacterial Resistance In Thailand

The Global Challenges Research Fund awarded the grant to an interdisciplinary group studying two species of antibiotic-resistant bacteria in Thailand.

Lion TCR Raises US$20 Million In Series A Funding

The funds will be used to advance clinical trials of LioCyx™, Lion TCR’s T-cell therapy against hepatocellular carcinoma.

WuXi To Establish Biologics Center In Northern China

The new biologics center in Shijiazhuang will include process development labs as well as clinical and commercial manufacturing facilities.

CStone Pharma Completes US$260 Million Series B Funding Round

The funds raised will primarily be used for clinical development of CS1001 and other clinical stage assets, as well as attract top industry talents.

WuXi STA Builds A New R&D Center In Shanghai

The new R&D center in Shanghai, China, will enable drug developers to accelerate their projects from preclinical to commercial stage.